Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Accounts Payables (2016 - 2025)

Plus Therapeutics has reported Accounts Payables over the past 16 years, most recently at $5.9 million for Q4 2025.

  • Quarterly Accounts Payables fell 47.55% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, down 47.55% year-over-year, with the annual reading at $5.9 million for FY2025, 47.55% down from the prior year.
  • Accounts Payables was $5.9 million for Q4 2025 at Plus Therapeutics, down from $11.6 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $11.6 million in Q3 2025 and troughed at $1.6 million in Q2 2021.
  • The 5-year median for Accounts Payables is $6.2 million (2023), against an average of $6.1 million.
  • The largest YoY upside for Accounts Payables was 426.11% in 2021 against a maximum downside of 55.4% in 2021.
  • A 5-year view of Accounts Payables shows it stood at $4.2 million in 2021, then soared by 101.49% to $8.4 million in 2022, then tumbled by 43.11% to $4.8 million in 2023, then surged by 137.24% to $11.3 million in 2024, then plummeted by 47.55% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Accounts Payables are $5.9 million (Q4 2025), $11.6 million (Q3 2025), and $6.4 million (Q2 2025).